LIR Life Sciences Corp.
SKNY
CNSX
| 10/31/2025 | |||||
|---|---|---|---|---|---|
| Revenue | -- | ||||
| Total Other Revenue | -- | ||||
| Total Revenue | -- | ||||
| Cost of Revenue | -- | ||||
| Gross Profit | -- | ||||
| SG&A Expenses | 49.68% | ||||
| Depreciation & Amortization | 25.00% | ||||
| Other Operating Expenses | -- | ||||
| Total Operating Expenses | 38.76% | ||||
| Operating Income | -38.76% | ||||
| Income Before Tax | -38.43% | ||||
| Income Tax Expenses | -- | ||||
| Earnings from Continuing Operations | -38.43% | ||||
| Earnings from Discontinued Operations | -- | ||||
| Extraordinary Item & Accounting Change | -- | ||||
| Minority Interest in Earnings | -- | ||||
| Net Income | -38.43% | ||||
| EBIT | -38.76% | ||||
| EBITDA | -38.87% | ||||
| EPS Basic | -35.19% | ||||
| Normalized Basic EPS | -35.29% | ||||
| EPS Diluted | -35.19% | ||||
| Normalized Diluted EPS | -35.29% | ||||
| Average Basic Shares Outstanding | 2.08% | ||||
| Average Diluted Shares Outstanding | 2.08% | ||||
| Dividend Per Share | -- | ||||
| Payout Ratio | -- | ||||